TapImmune to Present at Two Upcoming Investor Conferences

JACKSONVILLE, Fla., March 14, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the Sachs BioCapital USA Forum, held March 21st, 2018. He will also give a company presentation and live webcast at the 26th Annual Wall Street Investor Forum, held March 22nd, 2018. Both conferences will take place in New York City.

Sachs BioCapital USA Forum
Future of IO: Technologies & Market Opportunities Panel
Date: Wednesday, March 21, 2018
Time: 10:15 AM (Eastern Time)
Location: New York Academy of Sciences, Plenary Room

TapImmune Company Presentation
Date: Wednesday, March 21, 2018
Time: 3:00 PM (Eastern Time)
Location: The New York Academy of Sciences, Plenary Room (Presenting Track B)

26th Annual Wall Street Investor Forum
TapImmune Company Presentation
Date: Thursday, March 22, 2018
Time: 11:05 AM (Eastern Time)
Location: The University Club of NYC, 9th Floor (Track 1)

The audio webcast of the 26th Annual Wall Street Investor Forum will be accessible via the News and Events section of the TapImmune website: https://tapimmune.com/events. An archive of the audio will remain available for 90 days following the presentation.

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.

Back to news